-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Lowers Price Target to $12

Benzinga·11/21/2025 11:21:33
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and lowers the price target from $15 to $12.